Marc Garnick, MD, presented “The Importance of Diagnosing and Treating Oligometastatic Prostate Cancer and ADT Usage” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 22, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Garnick, Marc “The Importance of Diagnosing and Treating Oligometastatic Prostate Cancer and ADT Usage.” September 22, 2023. Accessed Aug 2024. https://grandroundsinurology.com/the-importance-of-diagnosing-and-treating-oligometastatic-prostate-cancer-and-adt-usage/
The Importance of Diagnosing and Treating Oligometastatic Prostate Cancer and ADT Usage – Summary
Dr. Marc Garnick explores the diagnosis and treatment of oligometastatic prostate cancer with the strategic use of androgen deprivation therapy (ADT). Advanced imaging techniques are essential for identifying oligometastatic disease, such as PET scans and advanced MRI. These technologies enhance the precision of detecting small metastatic lesions, facilitating timely and appropriate treatment decisions. By reducing androgen levels that fuel prostate cancer growth, the strategic use of ADT not only helps in controlling the primary tumor but also in managing metastatic lesions, thereby extending the therapeutic window and improving overall survival rates.
Dr. Garnick also addresses the timing and duration of ADT in the context of oligometastatic prostate cancer. He highlights individualized treatment plans based on patient-specific factors, including the extent of disease, patient health status, and response to initial therapies. This personalized approach ensures that patients receive the most effective treatment while minimizing potential side effects associated with prolonged ADT usage.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, where he also directs the hospital’s role as a tertiary cancer center for 7 affiliated community cancer centers. He has dedicated his career to the development of new therapies for prostate cancer. He serves as the Editor-in-Chief for The Annual Report on Prostate Diseases, formerly Perspectives on Prostate Disease. He served as the initial academic co-principal investigator for the commonly used prostate cancer drug leuprolide (Lupron). In addition to his academic affiliations, Dr. Garnick founded the Hershey Family Foundation for Prostate Cancer Research at Beth Israel Deaconess Medical Center, serves as medical adviser to World Book Encyclopedia, and is an active advisory member of several FDA panels and advisory committees. He has served on the boards of trustees of the Perelman School of Medicine at the University of Pennsylvania and of Penn Medicine. Dr. Garnick is also a Trustee Emeritus of Bowdoin College in Brunswick, Maine.
